Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of androgen-independent metastatic adenocarcinoma of the prostate, confirmed by 1 of the following:~  * Histologically confirmed disease~ * Pathologically documented disease and clinical course consistent with prostate cancer~* Castrate levels of testosterone with progressive disease by at least 1 of the following parameters:~  * 2 consecutively rising prostate-specific antigen levels, separated by at least 1 week, with at least 1 measurement that is 50% above the nadir reached after the last therapeutic maneuver (must be at least 5 ng/mL)~ * At least 1 new metastatic deposit on technetium Tc 99 bone scintigraphy~ * Progression of soft-tissue metastases by imaging or palpation, as indicated by:~    * Development of new area of malignant disease~   * At least 20% increase in sum of the longest dimension of target lesions~* Serum testosterone less than 50 ng/dL if no prior surgical castration~  * Luteinizing hormone-releasing hormone therapy must continue~* HLA-A2 positive~* No brain metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* More than 6 months~Hematopoietic~* Granulocyte count at least 1,500/mm\^3~* Lymphocyte count at least 500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* Bilirubin less than 1.5 mg/dL~* AST and ALT less than 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN OR~* Hepatic alkaline phosphatase fraction less than 2.5 times ULN~Renal~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 40 mL/min~* Proteinuria grade 0-1 OR~* Protein less than 1,000 mg by 24-hour urine collection~* No hematuria~* No abnormal sediment unless non-renal~Cardiovascular~* No unstable or newly diagnosed angina pectoris~* No myocardial infarction within the past 6 months~* No New York Heart Association class II-IV congestive heart failure~* No concurrent clinically significant cardiomyopathy requiring treatment~Immunologic~* No prior allergy or untoward reaction to vaccinia virus vaccination~* No altered immune function, including:~  * Eczema~ * Atopic dermatitis~ * HIV~ * Autoimmune disease~    * Autoimmune neutropenia~   * Thrombocytopenia~   * Hemolytic anemia~   * Systemic lupus erythematosus~   * Sjogren's syndrome~   * Scleroderma~   * Myasthenia gravis~   * Goodpasture syndrome~   * Addison's disease~   * Hashimoto's thyroiditis~   * Active Graves' disease~   * Multiple sclerosis~* No extensive psoriasis, severe acneiform rash, impetigo, varicella zoster, burns, or other traumatic or pruritic skin condition~* No known allergy to eggs~Other~* No other malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of the bladder~* No other life-threatening or serious illness~* No unhealed surgical scars~* No household or close physical contact with persons with any of the following conditions during or for 2 weeks after study treatment:~  * Eczema or eczematoid skin disorders~ * Acute, chronic, or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)~ * Pregnant or nursing women~ * Children under 5 years of age~ * Immunodeficient or immunosuppressed (including HIV positive) individuals~* No history of seizures or encephalitis~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior taxanes for metastatic prostate cancer~Endocrine therapy~* See Disease Characteristics~* At least 4 weeks since prior flutamide~* At least 6 weeks since prior bicalutamide or nilutamide~* No concurrent steroids except topical steroids, inhaled steroids for mild or moderate asthma, or decadron as premedication for chemotherapy~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~* No prior splenectomy~Other~* Recovered from prior therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete